Berman E
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
J Clin Pharmacol. 1992 Apr;32(4):296-309. doi: 10.1002/j.1552-4604.1992.tb03840.x.
Numerous clinical trials in adult patients with newly diagnosed acute myelogenous leukemia indicate that the survival rate is approximately 20%. A limited number of favorable prognostic features have been identified; patients who present with specific cytogenetic abnormalities such as t(15;17), t(8;21) and inv (16) tend to have survival rates approaching 40%. However, such patients constitute only a small proportion of the total denominator and it has therefore been a major focus of scientific endeavor to develop new drugs for the treatment of this disease. A wide variety of agents have undergone preliminary testing in this regard and include both natural substances such as homoherringtonine, a drug that has demonstrated modest complete remission rates in this disease and all-trans retinoic acid, a compound that has revolutionized the treatment of acute promyelocytic leukemia. This review will put in perspective some of the newer drugs for the treatment of acute myelogenous leukemia and allow for some conclusions to be drawn as to their impact in the treatment of this disease.
针对新诊断的成年急性髓性白血病患者开展的众多临床试验表明，生存率约为20%。已确定了一些有限的有利预后特征；出现特定细胞遗传学异常（如t(15;17)、t(8;21)和inv(16)）的患者生存率往往接近40%。然而，这类患者仅占总数的一小部分，因此，研发治疗该疾病的新药一直是科研工作的主要重点。在这方面，多种药物已进行了初步测试，包括天然物质，如高三尖杉酯碱（一种在该疾病中显示出一定完全缓解率的药物）和全反式维甲酸（一种彻底改变了急性早幼粒细胞白血病治疗方法的化合物）。本综述将对一些治疗急性髓性白血病的新药进行客观分析，并就它们对该疾病治疗的影响得出一些结论。
